Results 181 to 190 of about 29,074 (242)

Shared PRAME epitopes are T-cell targets in NUT carcinoma. [PDF]

J Immunother Cancer
Jensen JL, Peterson SK, Sambade MJ, Alley JR, Yu S, Kinjo T, Bennett SN, Vensko SP, Shabrang M, Debetta JD, Geyer JK, Price BA, Nickel KP, Kimple RJ, Kotecha RS, Herring LE, Davis IJ, Wang JR, French CA, Kuhlman B, Weiss JM, Rubinsteyn A, Vincent BG.   +22 more
europepmc   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, Volume 78, Issue 3, Page 566-581, March 2026.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Engineered neutrophil engagers overcome IgA limitations and reprogram resting neutrophils for cancer immunotherapy. [PDF]

J Biol Eng
Lee J, Han G, Kyung M, Lee S, Kim TW, Jung ST.   +5 more
europepmc   +1 more source

Development of a High‐Throughput LC–MS/MS Method for Simultaneous Quantification of Four Therapeutic Monoclonal Antibodies in Human Serum: Application in Clinical Therapeutic Drug Monitoring

Biomedical Chromatography, Volume 40, Issue 3, March 2026.
ABSTRACT Monoclonal antibody (mAb) therapies have revolutionized cancer treatment, significantly improving patient outcomes. However, the pharmacokinetics (PK) and pharmacodynamics (PD) of mAbs exhibit considerable variability due to nonlinear kinetics and individual differences, highlighting the need for therapeutic drug monitoring (TDM).
Yuan Yao, Guang‐Yao Huang, Ting‐Ting Wu, Ting‐Fei Tan, Feng‐Mei Hu, Chao Huang, Shan Gao, An‐Ping Guo, Jun‐Ping Wang   +8 more
wiley   +1 more source

Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Aim Tumor flare reaction (TFR) is characterized by an increase in tumor size during immunotherapy, often resembling disease progression. This study explores the relationship between anti‐tumor drugs and tumor flare reaction (TFR) through the FAERS database to assist clinicians in better patient management.
Wei Wang, Jiayuan Cui, Yuxuan Bo, Yuxuan Wang, Zhipeng Sun, Xin Guan, Baoan Hong, Ning Zhang   +7 more
wiley   +1 more source

UMG1 Defines a Targetable Subset of T‐Cell Lymphomas and Enables Precision Immunotherapy With a First‐in‐Class CD3ε Bispecific Engager [PDF]

Hematol Oncol
ABSTRACT T‐cell lymphomas (TCLs) account for a relatively small fraction of lymphoid malignancies and are characterized by highly aggressive course often refractory to current available therapies. We previously reported potent in vitro and in vivo antitumor activity of a Bispecific T‐Cell Engager (UMG1/CD3ε‐BTCE) directed against UMG1, a unique CD43 ...
Caracciolo D, Gentile C, Squillacioti S, Signorelli S, Riillo C, Faviana P, Conforti F, De Ieso K, Procopio E, Altomare E, Polerà N, Gaetano M, Balducci E, Beganovic O, Tuccillo F, Bonelli P, Grillone K, Lhermitte L, Tagliaferri P, Tassone P.   +19 more
europepmc   +2 more sources

Successful Use of Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma with Central Nervous System Involvement: A Case Report. [PDF]

Case Rep Oncol
Uemura Y, Togitani K, Nakashima J.
europepmc   +1 more source

Multiomic characterization of small cell lung cancer: Real‐world insights into therapeutic opportunities

Cancer, Volume 132, Issue 5, 1 March 2026.
NK, natural killer; STING, Stimulator of Interferon Genes; TCI, T‐cell inflamed. Abstract Background The dominant expression of lineage‐related transcription factors (TFs)—ASCL1, NEUROD1, POU2F3, and, controversially, YAP1—has enabled the classification of small cell lung cancer (SCLC) into distinct subtypes (SCLC‐A/N/P/Y, respectively).
Sonam Puri, Andrew Elliott, Abdul Rafeh Naqash, Hassan Abu Shukair, Kathleen C. Kerrigan, Shiven Patel, Andreas Seeber, Florian Kocher, Dipesh Uprety, Hirva Mamdani, Amit A. Kulkarni, Gilberto Lopes, Balazs Halmos, Hossein Borghaei, Wallace Akerley, Gabriel L. Sica, Stephen V. Liu, Trudy G. Oliver, Taofeek K. Owonikoko   +18 more
wiley   +1 more source

NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells. [PDF]

Oncoimmunology
Heger L, Kaszubowski T, Amon L, Lehmann CHK, Wingert S, Medina-Echeverz J, Koch J, Hackstein H, Purbojo A, Hartmann A, Alexiou C, Cesnjevar R, Pahl J, Dudziak D.   +13 more
europepmc   +1 more source

Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
In an ageing and inflamed haematopoietic ecosystem, clonal haematopoiesis and chronic lymphocytic leukaemia may originate from shared or parallel stem cell clones. This interaction modulates the effects of targeted therapies and contributes to cytopenias, cardiovascular toxicity, therapy‐related myeloid neoplasms and Richter transformation.
Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source